Financial Analysis: AEON Biopharma (AEON) versus Its Peers

AEON Biopharma (NASDAQ:AEON) is one of 1,060 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its rivals? We will compare AEON Biopharma to similar businesses based on the strength of its analyst recommendations, risk, earnings, institutional ownership, dividends, valuation and profitability.

Risk & Volatility

AEON Biopharma has a beta of 0.19, suggesting that its share price is 81% less volatile than the S&P 500. Comparatively, AEON Biopharma’s rivals have a beta of 3.71, suggesting that their average share price is 271% more volatile than the S&P 500.

Institutional & Insider Ownership

22.8% of AEON Biopharma shares are held by institutional investors. Comparatively, 44.1% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 23.5% of AEON Biopharma shares are held by company insiders. Comparatively, 13.7% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares AEON Biopharma and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AEON Biopharma	N/A	N/A	-994.63%
AEON Biopharma Competitors	-3,590.11%	-276.96%	-39.10%

Analyst Ratings

This is a breakdown of current recommendations and price targets for AEON Biopharma and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AEON Biopharma	0	0	1	0	3.00
AEON Biopharma Competitors	7772	21188	48893	1232	2.55

AEON Biopharma currently has a consensus target price of $5.00, suggesting a potential upside of 669.23%. As a group, “Pharmaceutical preparations” companies have a potential upside of 187.77%. Given AEON Biopharma’s stronger consensus rating and higher probable upside, research analysts clearly believe AEON Biopharma is more favorable than its rivals.

Earnings and Valuation

This table compares AEON Biopharma and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
AEON Biopharma	N/A	-$36.63 million	3.61
AEON Biopharma Competitors	$9.58 billion	$147.39 million	-5.43

AEON Biopharma’s rivals have higher revenue and earnings than AEON Biopharma. AEON Biopharma is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Summary

AEON Biopharma beats its rivals on 7 of the 13 factors compared.

About AEON Biopharma

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.